$28.5m for biotech start-ups with ‘moonshot ambitions’

3 minute read


MTPConnect is partnering with biotech companies CSL and Roche Diagnostics to help Australian startups commercialise their CVD and diabetes drugs and devices.


MTPConnect is partnering with biotech companies CSL and Roche Diagnostics to help Australian startups commercialise their CVD and diabetes drugs and devices.

This content is for Health Services Daily subscribers only.
or Join Now.

End of content

No more pages to load

Log In Register ×